Gene-directed enzyme prodrug therapy (GDEPT), or suicide gene therapy, has shown promise in clinical trials. In this preclinical study using stable cell lines and xenograft tumor models, we show that a triple-suicide-gene GDEPT approach produce enhanced therapeutic efficacy over previous methods. Importantly, all the three genes (thymidine kinase, cytosine deaminase and uracil phosphoribosyltransferase) function simultaneously as effectors for GDEPT and markers for multimodality molecular imaging (MMI), using positron emission tomography, magnetic resonance spectroscopy and optical (fluorescent and bioluminescent) techniques. It was demonstrated that MMI can evaluate the distribution and function/activity of the triple suicide gene. The concomitant expression of these genes significantly enhances prodrug cytotoxicity and radiosensitivity in vitro and in vivo.
INTRODUCTION
Multimodality molecular imaging (MMI), using positron emission tomography (PET), magnetic resonance spectroscopy (MRS) and optical (fluorescent and bioluminescent) techniques, offers powerful tools in unraveling biological processes in cancer diagnosis and treatment. 1 MMI also has a crucial role in developing and optimizing gene therapy for cancer, such as gene-directed enzyme prodrug therapy (GDEPT) or 'suicide gene therapy'. 2, 3 Suicide genes, such as herpes simplex virus type-1 thymidine kinase (HSV1-TK), cytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT), simultaneously function as effector genes for GDEPT and marker genes for MMI. As an effector, TK converts the prodrug ganciclovir (GCV) into toxic products and, as a marker, leads to the trapping of the marker substrate 124 I-FIAU (or 18 F-FEAU, 18 F-FHBG and so on) for PET imaging. [4] [5] [6] Similarly, CD and UPRT function as effector genes, with CD converting the prodrug 5-fluorocytosine (5-FC) to the chemotherapeutic drug 5-fluorouracil (5-FU) and UPRT converting 5-FU to the cytotoxic compound (fluoronucleotides, FNuc). As marker genes they permit MRS imaging (MRSI) of the spatial distributions of 5-FC, 5-FU and FNuc, thus assessing the function and activity of the CD and UPRT genes. [7] [8] [9] Individually, MRS and PET are powerful molecular imaging methods, each of which has contributed to improve cancer gene therapy. The combined use of both modalities may be even more powerful, motivating the development of combined PET/MRI units. 10, 11 As GDEPT employing single gene of HSV1-TK, CD, or UPRT has been demonstrated to be effective, efforts were focused on GDEPT combining two of these genes (double suicide gene therapy). Several studies have demonstrated that integrated CD/5-FC and HSV1-TK/GCV strategies is more effective with synergistic effects when compared with either strategy alone. 12, 13 Simultaneous expression of CD and UPRT genes could lead to synergistic effects resulting in increased sensitivity to 5-FC. 14, 15 Among double suicide gene therapy strategies, the combination of HSV1-TK/GCV and CD/5-FC is most widely studied and has been evaluated in clinical trials. 16, 17 Subsequently, a reporter gene system (the human sodium iodide symporter) was incorporated into a double suicide gene (TK/CD) adenovirus, and Na 99 m TcO 4 single-photon emission computed tomography images demonstrated gene expression after virus injection into human prostate cancer. 18 Thus, it was suggested that MMI can be used to monitor adenovirus-mediated suicide gene therapy. 18 The aim of the present preclinical study is to demonstrate that the therapeutic efficacy of the triple-suicide-gene approach is improved relative to previous methods, and that MMI can be used to monitor the delivery and evaluate the distribution and function/activity of the triple suicide gene.
MATERIALS AND METHODS Plasmids
Three plasmids were constructed: (1) pCMV-TK/enhanced green fluorescent protein (eGFP) contains the HSV1-tk and egfp fusion gene under the control of a cytomegalovirus (CMV) promoter and a neomycin-resistant gene, (2) pCMV-CD/monomeric dsred (mDsRed) containing the cd (of Saccharomyces cervisiae) and mDsRed fusion gene, and (3) pCMV-CD/UPRT/ mDsRed containing the cd, uprt (of Haemophilus influenzae) and mDsRed fusion gene under the control of the CMV promoter. The latter two plasmids contain the hygromycin B resistance gene.
Cell cultures and stably transfected cell lines R3327-AT rat prostate carcinoma cells were maintained in Dulbecco's Modified Eagle medium (Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum, 100 U ml À 1 penicillin and 100 mg ml À 1 streptomycin (Gemini, West Sacramento, CA, USA). The cells were cotransfected with two plasmids, pCMV-CD/mDsRed and pCMV-TK/eGFP, or pCMV-CD/UPRT/mDsRed and pCMV-TK/eGFP, using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Subsequently, the transfected cells were cultured in medium containing hygromycin B (0.2 mg ml À 1 ; Roche, Mannheim, Germany) and G418 (0.5 mg ml À 1 ; Calbiochem, San Diego, CA, USA). Stable transfectants were selected with fluorescence activated cell sorting using a cell sorter (MoFlo; Dako, Carpinteria, CA, USA). Single-cell-derived clones with the positive mDsRed and eGFP expression were isolated, expanded, their mDsRed and eGFP expression verified by flow cytometry and were used for further experiments. All cells were grown as monolayers at 37 1C in a humidified incubator with 5% CO 2 and 95% air. Stably transfected cells were designated as TKCD cells and TKCDUPRT cells, respectively (eGFP and mDsRed were omitted for simplicity).
Western blot analysis
The sheep anti-yCD polyclonal antibody was purchased from Biotrend (Cologne, Germany) and the anti-HSV1-TK monoclonal antibody was kindly provided by Dr WC Summers (Yale University, New Haven, CT, USA). The secondary antibodies were the horseradish peroxidase-labeled bovine anti-sheep IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or sheep anti-mouse IgG (Pierce, Rockford, IL, USA). The protein expression was visualized using the Supersignal chemiluminescent substrate (Pierce).
Flow cytometric analysis
The expression of eGFP and mDsRed was analyzed by flow cytometry using the cell sorter (MoFlo). Parental cells, cells constitutively expressing only TK/eGFP or CD/mDsRed, were analyzed in parallel as a negative control and eGFP-positive or mDsRed-positive controls, respectively.
Fluorescence microscopy
The cells were fixed with freshly prepared 4% paraformaldehyde for 10 min and rinsed twice with phosphate-buffered saline. The fluorescent images were acquired at 575 nm wavelength for mDsRed and at 488 nm for eGFP using a fluorescence microscope (Axiovert 200M, Carl Zeiss MicroImaging GmbH, Gö ttingen, Germany).
Drug cytotoxicity, radiation survival and colony-formation assay Cells were treated with GCV (Sigma-Aldrich, St Louis, MO, USA), 5-FC (InvivoGen, San Diego, CA, USA) or 5-FU (InvivoGen) at various concentrations for 24 h. Thereafter, cells were trypsinized, counted, serially diluted and plated into 60-mm dishes. After incubation for 10-14 days, colonies were stained with crystal violet and counted. Cell survival curves were constructed by plotting the surviving fractions as a function of drug concentration. For radiosensitization experiments, cells were treated with GCV or 5-FC alone or in combination for 24 h, and then irradiated with graded doses using a Cs-137 unit (Mark 1 model 68; Shephard and Associate, San Fernando, CA, USA) at B2.0 Gy min À 1 . Cell survivals were determined by colony-formation assay and plotted as a function of radiation doses.
Animal xenograft
Animal protocols were approved by the Institutional Animal Care and Use Committee at Memorial Sloan-Kettering Cancer Center. Tumor xenografts were formed by injecting 3 Â 10 6 cells subcutaneously into the hind legs of 6-to 8-week-old male nude mice (athymic nu/nu; NCI Frederick Cancer Research Institute, Frederick, MD, USA). Each tumor was measured with digital caliper in three orthogonal dimensions (a, b and c), and tumor volume was calculated as pabc/6. Experiments were performed when the tumors reached a volume of B500 mm 3 for imaging study, or a volume of B150 mm 3 for tumor growth delay study.
F MRS and MRS imaging
In vivo 19 F MRS was performed using a Bruker 7T spectrometer. 9 Mice were anesthetized with isoflurane and positioned in a specially designed animal holder. 19 F MR spectra were acquired and averaged over 10 min before and after the intravenous administration of 150 mg kg À 1 5-FU or 5-FC for a maximum of 1 h, using a single pulse with a time of repetition of 1 s and sweep width of 15 kHz. A glass sphere (18 ml) filled with 75 mmol l À 1 sodium fluoride (NaF) was used as an external reference for quantitation. The MR time domain data were analyzed using XsOs NMR (Columbia University, New York, NY, USA). The spectral area of the acquired data was obtained from a Lorentzian fit to the spectra after line broadening (30 Hz). Metabolite ratios were calculated by normalizing their resonance-peak areas to that of NaF. Graphic representation of the spectroscopic data (5-FC/NaF, 5-FU/NaF and FNuc/NaF) shows the average±s.d. of the given ratio at each time point.
Preceding the acquisition of 19 
I-FIAU microPET imaging
Two to three hours after MRS measurements, 7.4 MBq of 124 I-FIAU was intravenously injected with the thyroid blocked by adding SSKI (Super Saturated Potassium Iodide) to their drinking water 1 day ahead. The whole-body microPET images were acquired 16-18 h afterwards at the Focus 120 microPET scanner (Concorde Microsystems, Knoxville, TN, USA) under anesthesia. In general, a minimum of B10 million events were acquired in 20-40 min, depending on the administered activity and the time post injection. The image data were corrected for nonuniformity of response, dead time count losses and physical decay. An empirically determined system calibration factor was used to convert voxel count rates (adjusted for the 124 I branching ratio) to activity concentrations and the resulting data were normalized to the administered activity to yield percent of the injected dose per gram of tissue.
In vivo/ex vivo fluorescent imaging
Immediately after PET imaging, whole-body fluorescent images were acquired with a Maestro imaging system (CRi, Woburn, MA, USA) under anesthesia. The fluorescent images of eGFP and mDsRed were acquired using the 455 nm (435-480 nm) excitation per 490 nm long-pass emission filters and the 523 nm (503-548 nm) excitation per 560 nm long-pass emission filters, respectively. The images were unmixed with the tissue autofluorescence spectrum using linear least-squares optimization. After in vivo imaging, the tumors were dissected and their fluorescent images were acquired. Immediately after the ex vivo imaging, the tumors were embedded in OCT, frozen with dry ice and cut into 8-mm sections for autoradiography and fluorescent microscopy.
Autoradiography and fluorescent microscopy of tumor sections
To acquire the distributions of 124 I-FIAU in the tumor sections, phosphorplate imaging was employed with 13 h exposure. Digital autoradiographs were processed using a Fujifilm BAS-1800II bioimaging analyzer (Fuji Photo Film, Tokyo, Japan). Whole tumor eGFP and mDsRed fluorescent images from the same sections were acquired using a fluorescent microscope (Axiovert 200M) after the autoradiography exposure as previously described. 19 Tumor growth delay The mice bearing TKCD or TKCDUPRT tumors were divided into five groups and treated with (1) phosphate-buffered saline, (2) 500 mg kg À 1 5-FC plus 30 mg kg À 1 GCV, intraperitoneally administered (standard dose), (3) 25 mg kg À 1 5-FC plus 1.5 mg kg À 1 GCV intraperitoneally (low dose), (4) radiation (3 Gy) or (5) radiation combined with drug treatments (25 mg kg À 1 5-FC plus 1.5 mg kg À 1 GCV intraperitoneally, 2 h before radiation). The tumors were irradiated using the Cs-137 unit (Mark 1 model 68) within a home-made animal holder. The treatments were applied once a day for 5 days. Ten mice were used in each group. For six mice, the tumor volume was measured three times a week until the average volume reached B1500 mm 3 . The tumor volume relative to those at the beginning of treatments was calculated and plotted as a function of time after Triple suicide gene therapy and molecular imaging L Xing et al treatments. The difference in time (days) of tumor volume reaching B1500 mm 3 for treated groups relative to controlled group (relative growth delay) was calculated and compared. For other four mice, the tumors were dissected at 24 h after the last treatment, fixed with 4% paraformaldehyde, embedded with paraffin and cut into 4-mm sections for the immunohistochemistry staining.
Immunohistochemistry staining and imaging acquisition
The detection of proliferation and apoptosis in tumor sections was achieved by immunohistochemical staining using the rabbit anti-Ki-67 and anti-cleaved caspase-3 primary antibodies and goat anti-rabbit second antibodies, respectively (Cell Signaling Technology, Danvers, MA, USA). Finally, the sections were stained with hematoxylin and eosin. The sections were scanned on a digital histology platform (Mirax; Carl Zeiss, Gö ttingen, Germany) at Â 200 magnification. Composite images of sections were generated from individual microscopic images by the software Mirax viewer. Ki-67-and CCP3 staining positive cells were counted and compared between different groups.
Statistical analysis
Averages are presented as the mean ± s.e. Difference in cytotoxicity and radiosensitivity was determined using the Student's t-test. The difference in Ki-67 or CCP3 staining was analyzed using the Student's t-test, and tumor growth delay using one-way analysis of variance. A P-value of o0.01 was considered statistically significant. Figure 1a , analysis with anti-CD antibody revealed a 43-kDa band in the TKCD cell sample and the CD control (cells only expressing CDmDsRed), and a 66-kDa band in the TKCDUPRT cell sample and the CDUPRTmDsRed control (cells only expressing CDUPRTmDsRed). These bands corresponded to the predicted molecular weights of the various fusion proteins, respectively. As further validation, fluorescence activated cell sorting analysis showed that 96% of TKCD cells (Figure 1b, upper panel) and 98% of TKCDUPRT cells (Figure 1b , lower panel) are positive for both eGFP and mDsRed. Fluorescence microscopy of TKCD and TKCDUPRT cells exhibit strong eGFP and mDsRed signals (Figure 1c) .
The expression of TK and CD in the TKCD and TKCDUPRT cells enhanced the cellular sensitivity to GCV and 5-FC compared with that of the parental cells. Similarly, the expression of UPRT in the TKCDUPRT cells enhanced their sensitivity to 5-FU and 5-FC, relative to that of the TKCD cells (Figure 1d ). These observations evince the function and activity of the HSV1-TK, CD and UPRT enzymes in the transduced cells.
Multimodality and multiparametric molecular imaging When transplanted into nude mice, the TKCDUPRT cells form tumors, which allow multimodality and multiparametric imaging studies of transgene expression/function, all in the same tumor as illustrated in the schematics of Figure 2a .
As CD catalyzed the conversion of 5-FC to 5-FU, and UPRT facilitated that of 5-FU to 5-FUMP, Figure 1A) .
After the NMR studies, the same TKCDUPRT tumors were assessed for their constitutive expression of TK in vivo. The microPET images clearly showed significant uptake of 124 I-FIAU in the TKCDUPRT tumors, evincing the expression of TK (Figure 2c , and Supplementary Figure 1B) . Uptake in some normal tissues (bladder, thyroid and bowel) is also noted. For further corroboration, ex vivo nuclear imaging (autoradiography) was performed on tumor sections using a phosphor plate. The resulting images quantified the distribution of 124 I-FIAU radioactivity in the tumor sections with high spatial resolution of B50 mm (Figure 2e and Supplementary Figure 1D) .
Both eGFP and mDsRed expression were detected in the tumors in live mice (in vivo), or in excised tumors (ex vivo), as shown in Figure 2d and Supplementary Figure 1C , respectively. Fluorescent microscopic images (Figure 2f and Supplementary Figure 1E ) acquired for the same tumor section as in the autoradiograph (Figure 2e and Supplementary Figure 1D) showed similar overall distributions of eGFP, mDsRed and 124 I-FIAU.
The expression of TK, CD and UPRT on cell and tumor response to 5-FC, GCV and radiation In vitro, the simultaneous expression of these genes significantly enhances the cytotoxicity to GCV and 5-FC. Whereas TKCDUPRT cells were sensitive to GCV and 5-FC administered as single agent (Figure 1d ), concurrent treatment with both GCV and 5-FC resulted in much greater cytotoxicity (Figure 3a , left panel) with significant synergistic action between the two prodrugs (Supplementary Figure 2) . TKCD cells were also sensitive to combined treatment of GCV and 5-FC (Figure 3a, right panel) , but B20-fold higher 5-FC doses were needed to induce the similar levels of cytotoxicity.
To study the bystander effect, admixtures of parental and transfected cells, in the ratio of 4:1, were treated with GCV and 5-FC alone or in combination. The results (Supplementary Figures 3A and B) indicated that the admixture of parental and TKCDUPRT cells was much more sensitive than that of parental and TKCD cells for all treatment scenarios.
To provide in vivo validation of the efficacy of triple-suicidegene approach, tumor-bearing mice were treated with the standard doses of GCV (30 mg kg As was previously shown, expression TK, CD and UPRT led to enhanced response to produrg treatment. Here we present data showing that cells and tumors expressing TK, CD and UPRT, and treated with prodrugs are more radiosensitive. As shown in Figure 5a , TKCD and TKCDUPRT cells have similar radiosensitivity without prodrug. Single-agent treatment with GCV or 5-FC slightly enhanced the radiation response, but combined treatment with both 5-FC and GCV resulted into greater radiosensitization. In addition, the degree of radiosensitization is much higher in TKCDUPRT cells than TKCD cells, such that the 5-FC dose needed is only 1/50 to achieve the same radiosensitivity. A similar effect was observed for cell mixture of 80% parental and 20% TKCDUPRT cells (Supplementary Figure 2C) . In growth delay assay, radiation (3 Gy per fraction per day for 5 days) alone slightly delayed the tumor growth, but when combined with low-dose treatment of GCV and 5-FC it produced significant tumor growth delay (Figure 5b) . Again, the effect was greater in TKCDUPRT tumors. The relative growth delay (days) due to 5-FC þ GCV and 5-FC þ GCV þ radiation treatments was much longer in TKCDUPRT tumors than that in TKCD tumors (Po0.01).
DISCUSSION
In previous efforts, we constructed expressing vectors of CDUPRT fused with red fluorescent protein (mDsRed) and HSV1-TK fused with eGFP, and generated tumor models in which expression of the respective gene complexes can be monitored with MRS/ optical or PET/optical imaging, respectively. 7, 19 In the present study we report for the first time the triple-suicide-gene approach, using TK, CD and UPRT. Importantly, all three genes function simultaneously as effectors for GDEPT and markers for MMI. It is demonstrated that MMI can evaluate the distribution and Both PET and MRI techniques are important in developing and optimizing gene therapy, initially in laboratory setting and then translated into clinical studies. Jacobs et al. 20 employed 124 I-FIAU PET to monitor liposomal vector-mediated HSV1-TK gene expression in five patients with recurrent glioblastomas. Their preliminary findings showed that FIAU PET imaging of HSV-1-tk expression in patients is feasible and that vector-mediated gene expression may predict the therapeutic effect. Quantitative MRSI of 5-FU pharmacokinetics in patients has been reported previously. 21 Clinical trials of TKCD cancer gene therapy 16 suggest that MRSI and PET monitoring of gene therapy with MRSI and PET could have immediate implications for the investigation of gene therapy strategies. Our data clearly showed that the prodrug activation in TKCDUPRT-expressing tumor could be measured with 124 I-FIAU microPET (for TK) and 19 F-MRSI (for CDUPRT). As hybrid PET/MRI scanner has being developed from the preclinical prototype to clinical platforms, 22 visualization and quantification of triple suicide gene expression/ function in a single system will become available. There has been steady progress in applying GDEPT or suicide gene therapy to cancer treatment, from single suicide gene therapy (for example, using HSV1-TK with GCV, or CD with 5-FC) to the combined use of two suicide genes (for example, CD and HSV1-TK, or CD and UPRT), resulting in improved tumoricidal effect for different tumors. [12] [13] [14] [15] 23 Both the in vitro and in vivo data in the present study (Figures 3-5 and Supplementary Figure 2) clearly demonstrated that the triple-suicide-gene therapy approach is more effective in eradicating tumors than double suicide gene therapy employing HSV1-TK/GCV and CD/5-FC, which has been tested in clinical trials. 16, 17 The potential advantage of suicide gene therapy relevant for clinical application is its radiosensitization effect, as demonstrated in our study. We clearly showed that the coexpression of HSV1-TK, CD and UPRT triple genes not only significantly increased the sensitivity of GCV and 5-FC but also improved the radiosensitizing effect of GCV and 5-FC, relative to that induced by double suicide gene HSV1-TK and CD strategy ( Figure 5 ). In this regard, it has been shown that HSV1-TK/GCV gene therapy may inhibit the repair of radiationinduced sublethal DNA damage. 24 Others have suggested that the radiosensitization in CD/5-FC and CD/UPRT/5-FC approaches is mediated through the inhibition of thymidylate synthase by 5-FdUMP, resulting in the depletion of deoxythymidine monophosphate pools and increased DNA strand break, as well as redistribution of cells to the radiosensitive early S phase. 25 Previously, we have demonstrated that CDUPRT/5-FC approach has greater radiosensitization effect than the CD/5-FC system. 15 Therefore, it is not surprising that significant tumor control effects were found as triple-suicide-gene approach combined with radiation.
The difficulty in achieving efficient gene delivery to all cells in a tumor mass in vivo is a major limitation for successful cancer gene therapy. Therefore, the bystander effect is an important feature of suicide gene therapy, whereby the surrounding but untransduced cells are inactivated by the diffusion of toxic metabolites derived from the transduced cells. 26 Our data clearly demonstrated that a strong bystander effect was associated with the triple-suicidegene approach. Mixed cell populations in which only 20% of cells expressing TK, CD and UPRT were much more sensitive to GCV and 5-FC treatments than cells expressing TK and CD (Supplementary Figure 2A) . More importantly, an enhanced radiosensitizing effect was observed in the cell population that consisted only 20% cells expressing TK, CD and UPRT after treatment with GCV plus 5-FC (Supplementary Figure 2B) .
The studies were done in nude mice and eliminated the acquired immune response, which has been shown to be active, at least in the HSV1-tk therapy. It suggests that our approach might work better in intact animals. Although this study involved the use of stably transfected cell lines and associated tumor models with different transgene expression, drug sensitivity and growth rates, future studies plan to translate this strategy to clinical application. Specifically, we are generating adenovirus vectors armed with TK, CD and UPRT genes to deliver them into in vivo tumor models and to test whether triple gene transduction following GCV and 5-FC treatment will improve the efficacy of radiotherapy. As shown in present study, molecular imaging using PET and MRI can be used to monitor the function/activity of a triple suicide gene. Although the clinical utility of molecular imaging in suicide gene therapy must await clinical trials, we can illustrate its potential use with the following example. Suppose in a particular patient, PET and/or MRSI imaging suggest heterogeneity in the expressions of the TK or CD/UPRT genes in the tumor, one might consider additional injection of viral vectors to target that portion of the tumor with weak suicide gene expression. Clinical studies will be needed to evaluate this approach in cancer patients. ). Six mice were used for each group. Time of tumor volume reaching B1500 mm 3 relative to the controlled group was compared among groups (one-way analysis of variance). Error bars represent the s.e. of six mice. &: Po0.01, #: P40.01.
